Clinical Trials
27 trialsNCT02465060 2026-05-26
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06533059 2026-05-26
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
Phase 1 Active not recruiting
NCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06904365 2026-05-18
OvAR-Y
Washington University School of Medicine
Active not recruiting
NCT06043947 2026-05-15
SURVIMON
N.N. Petrov National Medical Research Center of Oncology
Active not recruiting
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT06628388 2026-04-29
JCDATAZONEWH
The University of Hong Kong
Phase NA Active not recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06874985 2026-04-03
Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation
International Agency for Research on Cancer
Phase NA Active not recruiting
NCT05891171 2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT07038369 2026-03-17
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT04644068 2026-02-19
PETRA
AstraZeneca
Phase 1/2 Active not recruiting
NCT03984695 2026-01-28
SHE-WOMEN
University of Kansas Medical Center
Phase NA Active not recruiting
NCT00579163 2026-01-07
Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT04141449 2025-12-31
Potlako+
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT04579380 2025-12-19
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
Seagen Inc.
Phase 2 Active not recruiting
NCT06572774 2025-11-24
C3Link
Implenomics
Phase NA Active not recruiting
NCT06036121 2025-08-17
A Study of ADRX-0706 in Select Advanced Solid Tumors
Adcentrx Therapeutics
Phase 1 Active not recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT05057013 2025-08-11
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Phase 1/2 Active not recruiting
NCT04140526 2025-05-23
PRESERVE-001
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT04802876 2025-03-21
ACROPOLI
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT06082882 2024-12-12
SEMM2
The University of Texas Health Science Center, Houston
Phase NA Active not recruiting
NCT05215574 2024-10-10
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
Phase 1 Active not recruiting
NCT04913337 2024-10-02
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
Phase 1/2 Active not recruiting
NCT04432857 2024-06-27
AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Active not recruiting